Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics

NACompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

April 12, 2022

Study Completion Date

April 12, 2022

Conditions
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
Interventions
DEVICE

Continuous Glucose Monitoring

CGM and frequent sample testing

Trial Locations (18)

22903

University of Virginia Center for Diabetes Technology, Charlottesville

30318

Atlanta Diabetes Associates, Atlanta

33612

University of South Florida, Tampa

38133

AM Diabetes and Endocrinology Center, Bartlett

78749

Texas Diabetes & Endocrinology, Austin

80045

Barbara Davis Center for Childhood Diabetes, Aurora

Barbara Davis Center for Diabetes, Aurora

83404

Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls

90505

SoCal Diabetes, Torrance

92025

AMCR Institute, Escondido

93105

Sansum Diabetes Research Institute, Santa Barbara

94598

Diablo Clinical Research, Inc., Walnut Creek

98057

Rainier Clinical Research Center, Inc., Renton

116089

Dalian Municiple Central Hospital, Dalian

200233

Shanghai Sixth People's Hospital, Shanghai

201102

Children's Hospital of Fudan University, Shanghai

210008

Nanjing First Hospital, Nanjing

310005

The Children's Hospital Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
lead

Medtronic Diabetes

INDUSTRY

NCT04436822 - Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics | Biotech Hunter | Biotech Hunter